Clear Targets in Pediatric Atopic DermatitisA Case-Based Update
This activity is jointly provided by Global Education Group and Integritas Communications.
There is no registration fee for attending this program.
This virtual symposium is not sponsored, endorsed, or accredited by the American Academy of Pediatrics.
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals
The educational design of this activity addresses the needs of pediatricians and other clinicians who are involved in the management of pediatric patients with atopic dermatitis.
This Case-in-Point™ program features an expert panel with a general pediatrician, and 2 pediatric specialists to address the challenges in treating young patients with moderate-to-severe atopic dermatitis. Faculty will discuss 3 cases of children with atopic dermatitis, comorbid asthma, and allergies, as well as disease-related psychosocial burden. This virtual symposium will cover the pathophysiologic underpinnings of atopic dermatitis, best practices in patient evaluation, common atopic and nonatopic comorbidities, clinical trial evidence for new and emerging pharmacotherapies, and recommended management strategies that emphasize shared decision-making with patients (and their caregivers) and a multidisciplinary approach in cases of more severe disease.
Upon completion of this activity, participants will be better able to:
- Differentially diagnose atopic dermatitis in pediatric patients, including identification of disease severity, phenotypes, and appropriate therapeutic interventions
- Compare the efficacy and safety of traditional immunosuppression modalities and biologic treatment options in moderate-to-severe atopic dermatitis
- Individualize treatment regimens for pediatric patients with moderate-to-severe atopic dermatitis to reflect disease presentation, comorbidities, and shared decision-making
- Discuss how to coordinate the ongoing management of moderate-to-severe atopic dermatitis based on communication and shared decision-making with patients, caregivers, and other clinicians
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.5 contact hour(s) (which includes XX hour(s) of pharmacology).
*Pharmacology hours will be determined after clinical content review.
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated
Americans With Disabilities Act
Event staff will be glad to assist you with any special needs. Please contact us prior to the live event at firstname.lastname@example.org.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the pretest, posttest, and program evaluation.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
The faculty have the following relevant financial relationships with ineligible companies:
Peter A. Lio, MD: Consultant: AbbVie, Almirall, Amyris, AOBiome, ASLAN, Bodewell, Burt's Bees, Dermavant, Eli Lilly, Exeltis, Galderma, IntraDerm, Johnson & Johnson, LEO, L'Oréal, Menlo Therapeutics, Micreos (stock options), Pierre Fabre, Pfizer, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, Unilever; Contracted Research: AbbVie, AOBiome, Regeneron/Sanofi Genzyme; Speakers Bureau: Eli Lilly, Galderma, LEO, L'Oréal, Pfizer, Regeneron/Sanofi Genzyme; Stock Shareholder: Altus Labs, Micreos; Royalty Theraplex AIM OTC ointment.
Anne Marie Singh, MD: Consulting Fee: AbbVie.
Corinna Rea, MD, MPH: Nothing to disclose.
The planners and managers have the following relevant financial relationships with ineligible companies:
Kristin Delisi, NP: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Kim Rodriguez: Nothing to disclose
Stacey Ullman: Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.